Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

BACKGROUND Pregnant patients with cancer are increasingly treated with anticancer drugs, although the specific impact of pregnancy-induced physiological changes on the pharmacokinetics (PK) of anticancer drugs and associated implications for optimal dose regimens remains unclear. Our objectives were to quantify changes in PK during pregnancy for four frequently used anticancer agents doxorubicin, epirubicin, docetaxel and paclitaxel, and to determine associated necessary dose adjustments. PATIENTS AND METHODS A pooled analysis of PK data was carried out for pregnant (Pr) and nonpregnant (NPr) patients for doxorubicin (n = 16 Pr/59 NPr), epirubicin (n = 14 Pr/57 NPr), docetaxel (n = 3 Pr/32 NPr) and paclitaxel (n = 5 Pr/105 NPr). Compartmental nonlinear mixed effect models were used to describe the PK and gestational effects. Subsequently, we derived optimized dose regimens aiming to match to the area under the concentration-time curve (AUC) in nonpregnant patients. RESULTS The effect of pregnancy on volumes of distribution for doxorubicin, epirubicin, docetaxel and paclitaxel were estimated as fold-change of <1.32, <2.08, <1.37 and <4.21, respectively, with adequate precision [relative standard error (RSE) <37%]. For doxorubicin, no gestational effect could be estimated on clearance (CL). For epirubicin, docetaxel and paclitaxel, a fold-change of 1.1 (RSE 9%), 1.19 (RSE 7%) and 1.92 (RSE 21%) were, respectively, estimated on CL. Calculated dose adjustment requirements for doxorubicin, epirubicin, docetaxel and paclitaxel were +5.5%, +8.0%, +16.9% and +37.8%, respectively. Estimated changes in infusion duration were marginal (<4.2%) except for paclitaxel (-21.4%). CONCLUSION Clinicians should be aware of a decrease in drug exposure during pregnancy and should not a priori reduce dose. The decrease in exposure was most apparent for docetaxel and paclitaxel which is supported by known physiological changes during pregnancy. The suggested dose adaptations should only be implemented after conduct of further confirmatory studies of the PK during pregnancy.

[1]  T. Fehm,et al.  Treatment of breast cancer during pregnancy: an observational study. , 2012, The Lancet. Oncology.

[2]  B. Green,et al.  Leveraging Physiological Data from Literature into a Pharmacokinetic Model to Support Informative Clinical Study Design in Pregnant Women , 2012, Pharmaceutical Research.

[3]  Horton,et al.  Annals of Oncology , 1991, Springer US.

[4]  Keishi Okamoto,et al.  Characterization of Individuals with Sacroiliac Joint Bridging in a Skeletal Population: Analysis of Degenerative Changes in Spinal Vertebrae , 2014, BioMed research international.

[5]  L. Hansson,et al.  Reference values for α1‐acid glycoprotein, α1‐antitrypsin, albumin, haptoglobin, C‐reactive protein, IgA, IgG and IgM during pregnancy , 2008, Acta obstetricia et gynecologica Scandinavica.

[6]  O. Mir,et al.  Increased evidence for use of chemotherapy in pregnancy. , 2012, The Lancet. Oncology.

[7]  A. C. Dubbelman,et al.  Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Vicini,et al.  The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics , 2012, British journal of clinical pharmacology.

[9]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[10]  F. Amant,et al.  Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Anderson.  Pregnancy-Induced Changes in Pharmacokinetics , 2005, Clinical pharmacokinetics.

[12]  J. Schellens,et al.  Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia. , 2013, British journal of clinical pharmacology.

[13]  L. Lagae,et al.  Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. , 2012, The Lancet. Oncology.

[14]  A. Miller,et al.  Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  E. Cardonick,et al.  Use of chemotherapy during human pregnancy. , 2004, The Lancet. Oncology.

[16]  H. Hollema,et al.  Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group , 2007, Clinical Cancer Research.

[17]  J. Schellens,et al.  Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy , 2014, BioMed research international.

[18]  M. Ratain,et al.  Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J. Schellens,et al.  Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. , 2010, British journal of clinical pharmacology.

[20]  F. Amant,et al.  Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study , 2010, Acta obstetricia et gynecologica Scandinavica.

[21]  M. Joerger.  Pharmacokinetic and pharmacogenetic profiling in solid cancer patients , 2007 .

[22]  F. Hytten,et al.  GLOMERULAR FILTRATION DURING AND AFTER PREGNANCY , 1974, The Journal of obstetrics and gynaecology of the British Commonwealth.

[23]  D. Koop,et al.  Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report. , 2006, Clinical Breast Cancer.

[24]  J. Schellens,et al.  Population Pharmacokinetic‐Pharmacodynamic Analysis of Trastuzumab‐Associated Cardiotoxicity , 2011, Clinical pharmacology and therapeutics.

[25]  T. Fehm,et al.  Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.